FDA's 510(k) transfer Q&A: what holders and buyers should check before a deal closes
New FDA question-and-answer guidance covers when a buyer of a 510(k) clearance needs no new submission and when the original submission number must be used.
What happened
On 19 November 2026, FDA published a question-and-answer guidance on transferring a 510(k) clearance between holders. Our records list the publication under FDA CBER. The document addresses common questions that arise when a 510(k) is sold or transferred. Two points stand out: when a new holder does not need to file a fresh submission, and when the original submission number must be used.
The records do not say whether the document is draft or final, whether it replaces earlier material, or what it says on each question. This analysis therefore sticks to the framing the record gives and does not guess at the detail. Teams should read the full text before acting on it.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this analysis is based on
- FDA publishes Q&A guidance on transferring a 510(k) clearance between holders FDA CBER · Thu 19 Nov 2026
- Allarity secures US patent on twice-daily stenoparib dosing, with protection expected into 2045 Allarity Therapeutics, Inc. · Thu 19 Nov 2026
- China approves HUTCHMED's Syk inhibitor SYVIK for chronic ITP and warm autoimmune haemolytic anaemia HUTCHMED (China) Ltd · Thu 19 Nov 2026
- Slovak regulator updates QRD Annex V after moving adverse reaction reporting form on its website ŠÚKL · Thu 19 Nov 2026
- AIFA adds YESAFILI aflibercept to simplified anti-VEGF monitoring form for four eye indications AIFA · Thu 19 Nov 2026
- Portugal's CNFT updates antibiotic guidance for hospitals and primary care, stressing stewardship links INFARMED · Thu 19 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Safety judgment belongs apart from the product line, and CBER just said so
FDA's new CBER Safety Council sits outside the product offices. PV leaders should test whether their own safety decisions have the same structural distance from commercial pressure.
Definitions decide pathways: UK gene therapy rewrite means check your category now
The UK will widen its gene therapy definition to catch synthetic and genome-editing products. Regulatory teams should test their pipelines against the new boundary before the legislation arrives.
EMA's CMV immunoglobulin PSUSA ends in maintenance: what a quiet outcome tells PV teams
EMA has closed its periodic safety review of cytomegalovirus immunoglobulin with the marketing authorisations maintained. What the outcome does and does not tell MAHs is worth spelling out.